At a glance
ClinicalIndex Comparison RecordN/ACompleted· 31 enrolled
Drug / intervention
Ondansetron and Placebo crossoverdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Ondansetron for Withdrawal Symptoms
In Brief
A clinical study evaluating Ondansetron and Placebo crossover for Substance Withdrawal Syndrome. Completed, enrolled 31 participants across 1 site.
Detailed Summary
We hope to determine whether Ondansetron, an anti-nausea medication, works to help relieve withdrawal symptoms experienced while the patient is being weaned off opioid medications. This medication has shown anecdotal evidence of being affective for the treatment of withdrawal symptoms and we hope to determine whether this is affective.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubstance Withdrawal Syndrome
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedJun 2008
Primary CompletionJul 2009
TodayJul 2026
First PostedJun 12, 2008
Enrollment StartMay 1, 2008
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.1 years ago
Interventions
Ondansetron and Placebo crossoverdrug